Fewer relapses and retreatments with ABSORICA LD™

Give your patients the possibility of achieving clearer skin after just one treatment cycle1,2


NOT ACTUAL PATIENT

For the treatment of severe recalcitrant nodular acne

Give your patients the chance for complete and prolonged remission1,2

95% did not require retreatment with isotretinoin1,2*

Phase IV trial analyzing efficacy of ABSORICA® (isotretinoin) based on per protocol population N=166; N=119 patients completed the post-treatment period

95%
No retreatment with isotretinoin
Retreatment with isotretinoin
82%
No retreatment with any acne medication (OTC or prescription)
Retreatment with acne medication

Most common adverse reactions (incidence ≥ 5%) are: dry lips, dry skin, back pain, dry eye, arthralgia, epistaxis, headache, nasopharyngitis, chapped lips, dermatitis, increased creatine kinase, cheilitis, musculoskeletal discomfort, upper respiratory tract infection, reduced visual acuity.

Please see full Important Safety Information.

Study Design

Achieve visibly clearer skin in one 5-month treatment cycle1-3*


More absorption means fewer retreatments and less scarring1,2,4*

  • To prevent new lesions and reduce risk of future scarring, appropriate patients should be treated early with an effective treatment like ABSORICA LD.

IMPORTANT SAFETY INFORMATION
Because of the risk of embryo-fetal toxicity, ABSORICA LD is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE® REMS.

Please see full Important Safety Information.

The majority of people should expect to see a 90% reduction in the number of nodules in one 5-month course of therapy2,5*